Paper30116751
Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients.
Liu J and 4 others. J Immunol Res, 2018. Cited by 38 papers, by iCite.
Cite this record
ConductScience Library. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients. Papers, record 30116751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30116751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CD4-Positive T-Lymphocytes | Major topic |
| CD8-Positive T-Lymphocytes | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Receptors, Immunologic | Major topic |
| Receptors, Tumor Necrosis Factor, Member 14 | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Tumor Escape |
Source PubMed
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28484077 | Epstein-Barr Virus-Induced VEGF and GM-CSF Drive Nasopharyngeal Carcinoma Metastasis via Recruitment and Activation of Macrophages. | Cancer Res | 2017 | https://conductscience.org/library/papers/28484077 | PubMed |
| 2 | 28123898 | BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma. | Oncoimmunology | 2016 | https://conductscience.org/library/papers/28123898 | PubMed |
| 3 | 24912948 | Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. | Hepatology | 2014 | https://conductscience.org/library/papers/24912948 | PubMed |
| 4 | 26681673 | Regulation of PD-L1: a novel role of pro-survival signalling in cancer. | Ann Oncol | 2016 | https://conductscience.org/library/papers/26681673 | PubMed |
| 5 | 24531850 | Hepatocellular carcinoma: clinical frontiers and perspectives. | Gut | 2014 | https://conductscience.org/library/papers/24531850 | PubMed |
| 6 | 28290464 | Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. | Cell Res | 2017 | https://conductscience.org/library/papers/28290464 | PubMed |
| 7 | 20307212 | Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM. | Annu Rev Immunol | 2010 | https://conductscience.org/library/papers/20307212 | PubMed |
| 8 | 22445654 | The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. | Curr Opin Pharmacol | 2012 | https://conductscience.org/library/papers/22445654 | PubMed |
| 9 | 25610743 | Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages. | Oncoimmunology | 2014 | https://conductscience.org/library/papers/25610743 | PubMed |
| 10 | 25621841 | The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? | Curr Opin Immunol | 2015 | https://conductscience.org/library/papers/25621841 | PubMed |
| 11 | 26484443 | Immunological landscape and immunotherapy of hepatocellular carcinoma. | Nat Rev Gastroenterol Hepatol | 2015 | https://conductscience.org/library/papers/26484443 | PubMed |
| 12 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 13 | 26146815 | World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. | Hepatology | 2015 | https://conductscience.org/library/papers/26146815 | PubMed |
| 14 | 26895379 | Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma. | Oncotarget | 2016 | https://conductscience.org/library/papers/26895379 | PubMed |
| 15 | 25858804 | Immune checkpoint blockade: a common denominator approach to cancer therapy. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25858804 | PubMed |
| 16 | 19426226 | The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. | Immunol Rev | 2009 | https://conductscience.org/library/papers/19426226 | PubMed |
| 17 | 30116751 | Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients. | J Immunol Res | 2018 | https://conductscience.org/library/papers/30116751 | PubMed |
| 18 | 23470321 | Molecular mechanisms of T cell co-stimulation and co-inhibition. | Nat Rev Immunol | 2013 | https://conductscience.org/library/papers/23470321 | PubMed |
| 19 | 20147741 | Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. | Ann Oncol | 2010 | https://conductscience.org/library/papers/20147741 | PubMed |
| 20 | 25605845 | Immune Checkpoint Blockade in Cancer Therapy. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25605845 | PubMed |
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41471273 | BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41471273 | PubMed |
| 41319234 | CD160-Derived Peptide as a Bidirectional Inhibitor Toward Immune Checkpoints BTLA/HVEM and HVEM/LIGHT. | J Med Chem | 2025 | https://conductscience.org/library/papers/41319234 | PubMed |
| 41112836 | Immune checkpoint biology in hepatocellular carcinoma (Review). | Oncol Lett | 2025 | https://conductscience.org/library/papers/41112836 | PubMed |
| 40463377 | B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer. | Front Immunol | 2025 | https://conductscience.org/library/papers/40463377 | PubMed |
| 40243455 | Increased Herpesvirus Entry Mediator Expression on Circulating Monocytes and Subsets Predicts Poor Outcomes in Pancreatic Ductal Adenocarcinoma Patients. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40243455 | PubMed |
| 40001057 | Assessing the causal association between 731 immunophenotypes and the risk of colorectal cancer: a Mendelian randomization study. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40001057 | PubMed |
| 39956885 | CD28 Superfamily Costimulatory Molecules in Chronic Pain: Focus on Immunomodulation. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/39956885 | PubMed |
| 38939518 | Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients. | Oncoimmunology | 2024 | https://conductscience.org/library/papers/38939518 | PubMed |
| 38835768 | The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients. | Front Immunol | 2024 | https://conductscience.org/library/papers/38835768 | PubMed |
| 38785930 | Herpesvirus Entry Mediator as an Immune Checkpoint Target and a Potential Prognostic Biomarker in Myeloid and Lymphoid Leukemia. | Biomolecules | 2024 | https://conductscience.org/library/papers/38785930 | PubMed |
| 38233898 | BTLA biology in cancer: from bench discoveries to clinical potentials. | Biomark Res | 2024 | https://conductscience.org/library/papers/38233898 | PubMed |
| 37041226 | BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia. | Cancer Immunol Immunother | 2023 | https://conductscience.org/library/papers/37041226 | PubMed |
| 34531847 | Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy. | Front Immunol | 2021 | https://conductscience.org/library/papers/34531847 | PubMed |
| 34484870 | Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma. | Oncoimmunology | 2021 | https://conductscience.org/library/papers/34484870 | PubMed |
| 34385315 | Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34385315 | PubMed |
| 33917094 | BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33917094 | PubMed |
| 33859648 | Roles of BTLA in Immunity and Immune Disorders. | Front Immunol | 2021 | https://conductscience.org/library/papers/33859648 | PubMed |
| 33564688 | Association of BTLA Polymorphisms with Susceptibility to Non-Small-Cell Lung Cancer in the Chinese Population. | Biomed Res Int | 2021 | https://conductscience.org/library/papers/33564688 | PubMed |
| 33365080 | High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma. | Oncol Lett | 2021 | https://conductscience.org/library/papers/33365080 | PubMed |
| 33238640 | Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33238640 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| BTLA | 151888 | PubTator's text mining | https://conductscience.org/library/genes/151888 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| GPT | 2875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TENM1 | 10178 | PubTator's text mining | https://conductscience.org/library/genes/10178 | NCBI Gene |
| TNFRSF14 | 8764 | PubTator's text mining | https://conductscience.org/library/genes/8764 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30116751
GET https://conductscience.org/api/papers/v1/30116751/references?page=2